<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639574</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0030</org_study_id>
    <nct_id>NCT00639574</nct_id>
  </id_info>
  <brief_title>Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi</brief_title>
  <official_title>Interest of Néfopam in the Treatment of Pain During the Intense Ureteral Calculi Uncomplicated in Adults in Emergencies Unit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The administration of néfopam after initial treatment by kétoproféne, could obtain, in&#xD;
      patients remaining pain and classically need morphine, analgesia at least the same as&#xD;
      morphine alone. The use of néfopam second line after ketoprofen could reducing (or even&#xD;
      eliminating) the need for morphine (and its side effects), allowing a reduction in the length&#xD;
      of stay of patients in the emergency unit.&#xD;
&#xD;
      The main objective is to show that the addition of a néfopam initial treatment with the&#xD;
      kétoproféne, reduces, in patients with ureteral calculi, the percentage of patients requiring&#xD;
      the use of a treatment by morphine.&#xD;
&#xD;
      The secondary objective is to reduce the side effects caused by the morphine, shorten the&#xD;
      time to install the appropriate level of analgesia while reducing the risk of failure of the&#xD;
      titration morphine, reduce the time spent on titration of morphine and reduce the length of&#xD;
      stay patient intake in emergency unit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is prospective, parallel, double-blind, randomized, placebo-controlled analysis&#xD;
      with intent to treat. There are 2 groups:&#xD;
&#xD;
        -  A group N: néfopam&#xD;
&#xD;
        -  A group P: placebo And all the patient receive, before randomization, 100 mg of&#xD;
           ketoprofen (Profenid ®) on 20 minutes.&#xD;
&#xD;
      The number of subjects is 52.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need to use morphine as an analgesic scheme (binary yes/no)</measure>
    <time_frame>As analgesic scheme</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of morphine consumed after titration (mg and number of bolus)</measure>
    <time_frame>After titration and after administration of placebo or néfopam</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (measured by the EVA) after administration of placebo or néfopam</measure>
    <time_frame>After titration and after administration of placebo or néfopam</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified verbal Scale of Satisfaction</measure>
    <time_frame>After titration and after administration of placebo or néfopam</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Ureteral Calculi, Hyperalgic, Not Complicated</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Néfopam</intervention_name>
    <description>There are two groups :&#xD;
a group N : néfopam&#xD;
a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 to 50 years old.&#xD;
&#xD;
          -  Admitted to the emergency room for typical ureteral calculi with severe pain (VAS &gt; or&#xD;
             = 60), and microscopic hematuria in the strip without signs of urinary complications.&#xD;
&#xD;
          -  Preliminary Agreement patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient disagree.&#xD;
&#xD;
          -  Pregnant women (sought by the questioning).&#xD;
&#xD;
          -  Fever &gt; 38 ° C.&#xD;
&#xD;
          -  Leucocyturie or nitriturie (dipstick).&#xD;
&#xD;
          -  Contraindication to ketoprofen.&#xD;
&#xD;
          -  Contraindication to néfopam.&#xD;
&#xD;
          -  Contraindication to morphine.&#xD;
&#xD;
          -  Contraindication linked to drug interactions as mentioned in the Summary of Product&#xD;
             Characteristics of the Authorization for placing on the market of Acupan ®.&#xD;
&#xD;
          -  Treatment opioid analgesics, nonsteroidal anti-inflammatory or inflammatory or&#xD;
             paracetamol in the previous 12 hours.&#xD;
&#xD;
          -  Secondary exclusion to a urinary tract infection or systemic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moustafa Fares, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>March 26, 2010</last_update_submitted>
  <last_update_submitted_qc>March 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Moustafa Farès</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Pain, morphine, nefopam, co analgesia, ureteral calculi, emergency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

